enGene (NASDAQ:ENGN) Shares Gap Down to $15.74

Shares of enGene Holdings Inc. (NASDAQ:ENGN) gapped down before the market opened on Thursday . The stock had previously closed at $15.74, but opened at $15.34. enGene shares last traded at $15.34, with a volume of 1,122 shares changing hands.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the stock. Leerink Partnrs reissued an “outperform” rating on shares of enGene in a research report on Tuesday, February 20th. SVB Leerink assumed coverage on shares of enGene in a research report on Tuesday, February 20th. They set an “outperform” rating and a $31.00 price target for the company. Morgan Stanley started coverage on enGene in a research report on Friday, March 8th. They issued an “overweight” rating and a $40.00 price objective on the stock. UBS Group began coverage on enGene in a research report on Thursday, March 28th. They issued a “buy” rating and a $37.00 target price for the company. Finally, Guggenheim initiated coverage on enGene in a research note on Monday, April 15th. They issued a “buy” rating and a $34.00 target price for the company. Five analysts have rated the stock with a buy rating, According to MarketBeat, enGene currently has a consensus rating of “Buy” and an average target price of $35.50.

enGene Stock Performance

The business has a 50 day simple moving average of $15.97.

Institutional Trading of enGene

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Citadel Advisors LLC purchased a new stake in enGene during the 4th quarter worth approximately $185,000. Goldman Sachs Group Inc. bought a new stake in shares of enGene in the fourth quarter worth $346,000. Royal Bank of Canada acquired a new stake in enGene in the fourth quarter valued at $349,000. Vivo Capital LLC bought a new position in enGene during the 4th quarter valued at $6,264,000. Finally, Omega Fund Management LLC acquired a new position in enGene during the 4th quarter worth $10,441,000. 64.16% of the stock is owned by hedge funds and other institutional investors.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.